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This post hoc analysis of a phase 3 trial explored the effect of pixantrone in
patients (50 pixantrone, 47 comparator) with relapsed or refractory aggres-
sive B-cell non-Hodgkin lymphoma (NHL) confirmed by centralized histo-
logical review. Patients received 28-d cycles of 85 mg/m2 pixantrone
dimaleate (equivalent to 50 mg/m2 in the approved formulation) on days
1, 8 and 15, or comparator. The population was subdivided according to
previous rituximab use and whether they received the study treatment as
3rd or 4th line. Median number of cycles was 4 (range, 2–6) with pix-
antrone and 3 (2–6) with comparator. In 3rd or 4th line, pixantrone was
associated with higher complete response (CR) (231% vs. 51% compara-
tor, P = 0047) and overall response rate (ORR, 436% vs. 128%,
P = 0005). In 3rd or 4th line with previous rituximab (20 pixantrone, 18
comparator), pixantrone produced better ORR (450% vs. 111%,
P = 0033), CR (300% vs. 56%, P = 0093) and progression-free survival
(median 54 vs. 28 months, hazard ratio 052, 95% confidence interval
026–104) than the comparator. Similar results were found in patients
without previous rituximab. There were no unexpected safety issues.
Pixantrone monotherapy is more effective than comparator in relapsed or
refractory aggressive B-cell NHL in the 3rd or 4th line setting, indepen-
dently of previous rituximab.
Keywords: pixantrone, salvage therapy, B-cell non-Hodgkin lymphoma,
rituximab, post hoc study.
Pixantrone is conditionally approved in Europe for the man-
agement of multiply relapsed or refractory aggressive B-cell
non-Hodgkin lymphoma (NHL), on the basis of results from
an open-label, randomized phase 3 study comparing pix-
antrone with physician’s choice of treatment in 140 patients
with relapsed or refractory aggressive NHL (Pettengell et al,
2012). Treatment of heavily pre-treated patients with pix-
antrone was reported to be efficacious and tolerable. The rate
of complete response (CR) or unconfirmed complete
response (CRu) with pixantrone was 200% [95% confidence
interval (CI), 114–313%] vs. 57% (95% CI 16–140%)
with comparator (P = 0021). Treatment with pixantrone
was also associated with a longer progression-free survival
(PFS) than comparator (53 vs. 26 months, P = 0005). The
most common grade 3 or 4 adverse events with pixantrone
were uncomplicated neutropenia, leucopenia and thrombocy-
topenia, all of which were manageable and in line with what
would be expected for administration of a cytotoxic agent to
heavily pre-treated patients.
There are currently a number of first-line treatment
options in patients with aggressive B-cell NHL, including
anthracycline-based regimens, with or without rituximab.
Overall response rates (ORR) can reach 75% (Coiffier et al,
2010). However, there is less consensus on salvage regimens
for the 25–35% of patients who fail to respond or relapse
after first-line therapy with standard protocols. Options
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include platinum-containing regimens and autologous stem
cell transplantation, though prognosis remains relatively poor
(Chao, 2013). Pixantrone is currently the only salvage ther-
apy with regulatory approval for patients with relapsed or
refractory aggressive B-cell NHL (Boyle & Morschhauser,
2015). The approval is conditional and confirmatory trials
on pixantrone are underway. In the meantime, it is impor-
tant to use all available data to further explore efficacy and
safety in the patients for which it is approved.
This report describes a post hoc analysis of the phase 3
study described above (Pettengell et al, 2012) with the aim of
investigating the effect of pixantrone in a subpopulation of
patients with relapsed or refractory aggressive B-cell NHL, as
confirmed by centralized independent pathological review.
We also explored the effect of pixantrone or comparator in
this population divided according to whether they were
receiving the study treatment as their 3rd or 4th line of ther-
apy or as any line of therapy (i.e. all patients, including those
receiving therapy as 3rd or 4th line and above), as well as
whether they had previously received rituximab treatment or
not.
Patients and methods
Main study design and treatment
The design and methods of this phase 3 study have been
described (Pettengell et al, 2012). Briefly, this multicentre,
open-label, randomized trial included patients with aggressive
de novo or transformed NHL [according to the Revised
European American Lymphoma (REAL) and World Health
Organization (WHO) classifications], who had relapsed or
were refractory to two or more previous lines of chemother-
apy regimens, including at least one standard anthracycline-
based regimen with response ≥24 weeks. The protocol was
amended during the study to exclude patients with no previ-
ous treatment with rituximab in countries where it was
commercially available. Eligible patients had European Coop-
erative Oncology Group (ECOG) performance status 0–2,
measurable disease, no persisting toxicities from previous
lines of treatment and adequate bone marrow and organ
function. Patients who had received more than 450 mg/m2
doxorubicin or equivalent were excluded from the study, as
were patients with clinically significant cardiovascular abnor-
malities with left ventricular ejection fraction (LVEF) less
than 50% and New York Heart Association grade 3 or 4
heart failure.
The trial was performed in 66 hospital centres in Europe,
India, Russia, South America, the UK and the USA between
October 2004 and March 2008. All patients provided written
informed consent and local ethical approval was obtained in
all centres. The study was registered (www.ClinicalTrials.gov,
NCT00088530).
Patients were randomly allocated pixantrone or com-
parator. The patients in the pixantrone group received
28-d cycles of 85 mg/m2 pixantrone dimaleate (equivalent
to 50 mg/m2 in the base formulation approved by the
European regulatory authorities) by intravenous infusion
over 1 h on days 1, 8 and 15. The choice of compara-
tor was left to the treating physician and could be
vinorelbine, oxaliplatin, ifosfamide, etoposide, mitox-
antrone or gemcitabine, all of which were given at pre-
specified standard doses and schedules (Pettengell et al,
2012). Randomization was achieved by an interactive
voice response system and was stratified by region (USA
versus Western Europe versus the rest of the World),
International Prognostic Index (≤1 vs. ≥2) and previous
stem cell transplantation. Patients were followed for
18 months after last treatment intake for disease progres-
sion and survival.
Post hoc study design
Our post hoc analysis included only patients with confirma-
tion of histology by blinded centralized review of the lymph
node biopsy or a tissue sample. In the main study protocol,
histology was performed by an onsite pathologist and, in
view of the urgent need for therapy, patients could be
included in the main trial on the basis of this local evalua-
tion (Pettengell et al, 2012). A second pathological evaluation
was performed centrally and diagnosis involved consensus of
two (or three in case of disagreement) independent patholo-
gists. Diagnosis was identified as diffuse large B-cell lym-
phoma (DLBCL), grade III follicular lymphoma, or
transformed indolent lymphoma (i.e. confirmation that cur-
rent disease was high-grade DLBCL or grade III follicular
lymphoma -like in patients with a history of indolent
disease).
In our post hoc analysis, we explored outcomes in all
patients with histological confirmation of aggressive B-cell
NHL by centralized review. We also further subdivided this
population to explore outcomes in the subgroup of patients
receiving study treatment as a 3rd or 4th line (i.e. excluding
patients receiving it as 5th line or higher) and patients
receiving it as any line of therapy and those with or without
prior treatment with rituximab.
The primary outcome was the efficacy of pixantrone versus
a selection of single agents in terms of proportion of patients
who achieved CR or CRu in the intention-to-treat (ITT)
population at end of treatment. Tumour response was
assessed by an independent panel of three experts (a radiolo-
gist, an oncologist and a pathologist), who were blinded to
both treatment assignment and the evaluation of response by
the onsite pathologist. Response criteria were based on the
1999 International Working Group criteria (Cheson et al,
1999, 2007; Pettengell et al, 2012). Secondary outcomes
included the proportion of people who achieved an overall
response (CR, CRu, partial response and ORR), and length
of PFS and overall survival (OS). All adverse events were
recorded.
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Statistical methods
Descriptive statistics were used for baseline characteristics,
adverse events and response rates. Values are presented as
medians (range) or numbers (percentages). The difference
between pixantrone and comparator in terms of CR and
ORR was evaluated using a Fisher’s exact test and the corre-
sponding P values are presented. The level of statistical sig-
nificance was set at 5%. Survival (PFS and OS) was analysed
using the method of Kaplan and Meier and an unstratified
log-rank test. A Cox proportional hazards model was used to
calculate the differences in PFS and OS between pixantrone
and comparator, which are presented as a hazard ratio (HR)
with the corresponding 95% CI. Statistical analyses were per-
formed using SAS version 9.2 software (SAS Institute Inc.,
Cary, NC, USA).
Results
A total of 140 patients (pixantrone/comparator; n = 70/70)
were included in the main study, of whom 126 had aggres-
sive B-cell NHL as determined by on-site histology (Fig 1).
Of these 126 patients, 99 patients (pixantrone/comparator,
n = 50/49) were receiving study treatment as their 3rd or 4th
line of treatment.
A total of 97 of the 140 patients (692% of the original
study population) had aggressive B-cell NHL according to
centralized review (50 patients treated with pixantrone, 47
patients treated with comparator). The rate of concordance
of onsite review with centralized review was 76%. The
reasons for exclusion from our post hoc analysis were lack of
consensus on aggressive disease (20 patients treated with pix-
antrone, 17 patients treated with comparator) or no material
for centralized review (3 patients treated with pixantrone, 3
patients treated with comparator).
The baseline characteristics of the 97 histologically con-
firmed patients are presented in Table I. The median age of
the population was 600 years (range 28–80 years) in the pix-
antrone group and 58 years (26–77 years) in the comparator
group. There were fewer women in the pixantrone group
(38% vs. 49%, respectively). Most of the patients had DLBCL
(82 patients, 85%), with lesser proportions of transformed
indolent lymphoma (12 patients, 12%) and grade III follicu-
lar lymphoma (3 patients, 3%). Three quarters of the popu-
lation had an International Prognostic Index ≥2 (72 patients,
74%) and/or Ann Arbor stage III or IV (72 patients, 74%).
About half the population had one or more extranodal sites
(46 patients, 47%). Fifty-six patients (58%) had previously
received rituximab (30 pixantrone, 26 comparator) (Fig 1).
More than three quarters of the population (78 patients,
80%) had previously received two or three lines of therapy
(39 pixantrone, 39 comparator), of whom 38 patients (20
pixantrone, 18 comparator) had previously received ritux-
imab (Fig 1). There were no relevant differences between the
post hoc population and the population of the main study
(Pettengell et al, 2012) in terms of demographic characteris-
tics, diagnosis, or previous chemotherapy.
The median number of drug cycles received during the
study was four (range, two to six) in the pixantrone group
and three (range, two to six) in the comparator group. More
Fig 1. Trial profile. NHL, non-Hodgkin lymphoma.
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patients began a sixth cycle of study treatment in the pix-
antrone group [22 of 68 (324%)] than in the comparator
group [19 of 67 (284%)].
Treatment with pixantrone was associated with a trend to
higher response rates than comparator in patients with histo-
logically confirmed aggressive B-cell NHL (Tables II and III).
When it was administered as 3rd or 4th line therapy in
patients with histologically confirmed disease by central
review, the rate of CR or CRu was 231% with pixantrone vs.
51% with comparator (P = 0047) and ORR was 436% with
pixantrone vs. 128% with comparator (P = 0005)
(Table II). In the 38 patients who had previously received
rituximab who were receiving the study treatment as a 3rd
or 4th line therapy, there was also a significantly better ORR
with pixantrone than comparator (45% vs. 111%,
P = 0033) and a trend for a better rate of CR or CRu
(300% vs. 56%, P = 0093) (Table III). The PFS with pix-
antrone in these patients was 54 vs. 28 months for com-
parator (HR 052, 95% CI 026–104) (Fig 2A).
Similar results were found in the 41 patients who had not
previously received rituximab (Table III). Treatment with
pixantrone was associated with better response in terms of
rate of CR or CRu (150% with pixantrone vs. 48% with
comparator at the end of treatment, P = 0343) and ORR
(45% vs. 143%, P = 0043). In the 40 patients without pre-
vious rituximab receiving the study treatment as a 3rd or 4th
line therapy, the PFS was 61 vs. 35 months for comparator
(HR 036, 95% CI 018–073) (Table III, Fig 2B).
The safety profile of pixantrone in patients with aggressive
B-cell NHL was in line with the previously published results
of the main study (Pettengell et al, 2012) and current knowl-
edge on the agent. Uncomplicated neutropenia was more
common in the pixantrone group than in the comparator
group: all grades represented 500% pixantrone vs. 239%
comparator; grades 3 or 4 represented 412% pixantrone,
194% comparator. These adverse events were noncumulative
and generally lasted less than 3 d. Grade 4 neutropenia
occurred at a rate of approximately 10% per cycle with no
increase in later cycles. Adjunctive therapy with granulocyte
colony stimulating factor was not required in any patient.
Other grade 3 or 4 haematological adverse events including
leukopenia (235% pixantrone, 75% comparator) and
thrombocytopenia (118% pixantrone, 104% comparator)
Table I. Baseline characteristics in 97 patients
with aggressive B-cell non-Hodgkin lymphoma,
according to centralized pathological review.
Patients with aggressive B-cell non-Hodgkin
lymphoma (N = 97)
Pixantrone (n = 50) Comparator (n = 47)
Age, years 600 (28–80) 580 (26–77)
Female 19 (380%) 23 (489%)
Diagnosis
Diffuse large B-cell lymphoma 41 (820%) 41 (872%)
Transformed indolent lymphoma 7 (140%) 5 (106%)
Grade III follicular lymphoma 2 (40%) 1 (21%)
International Prognostic Index
Score 0–1 12 (240%) 13 (277%)
Score ≥2 38 (760%) 34 (723%)
Ann Arbor stage
Stage I or II 13 (260%) 12 (255%)
Stage III or IV 37 (740%) 35 (745%)
≥1 extranodal site 24 (480%) 22 (468%)
Previous chemotherapy
Number of lines 30 (2–9) 30 (2–8)
Two or three lines only 39 (780%) 39 (830%)
Previous rituximab 30 (600%) 26 (553%)
Values are medians (range) or numbers and percentages.
Table II. Response rates (CR, CR or CRu, ORR) until the end of
study in patients with aggressive B-cell non-Hodgkin lymphoma
receiving their 3rd or 4th line of therapy.
Pixantrone Comparator P-value*
Patients with aggressive B-cell non-Hodgkin lymphoma determined
by on-site histology (n = 99)
Number of patients 50 49
CR, n (%) 9 (180%) 0 (00%) 0003
CR or CRu, n (%) 14 (280%) 2 (41%) 0002
ORR, n (%) 24 (480%) 6 (122%) <0001
Patients with aggressive B-cell non-Hodgkin lymphoma with
histology determined by central review (n = 78)
Number of patients 39 39
CR, n (%) 7 (179%) 0 (00%) 0012
CR or CRu, n (%) 9 (231%) 2 (51%) 0047
ORR, n (%) 17 (436%) 5 (128%) 0005
CR, complete response; CRu, unconfirmed complete response; ORR,
overall response rate.
*P value versus comparator (Fisher exact test).
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were more frequent in the pixantrone group. As regards
non-haematological adverse events, all-grade diarrhoea was
reported more frequently with comparator (44% pixantrone,
179% comparator) and all-grade cough with pixantrone
(221% pixantrone, 45% comparator). The rate of cardiac
events did not increase with increasing pixantrone exposure
and were predominantly asymptomatic (grade 1 and 2 decli-
nes in LVEF).
Discussion
Our post hoc analysis confirms the efficacy of pixantrone
in patients with relapsed or refractory aggressive B-cell
NHL with up to 3 prior therapeutic regimens and demon-
strates concordance for efficacy data even when the histo-
logical diagnosis was performed locally and confirmed by
an independent histological review (Pettengell et al, 2012).
Monotherapy with pixantrone is more effective than physi-
cians’ choice of therapy in the 3rd or 4th line (histologi-
cally confirmed disease by central review) setting with a
CR or CRu of 231% vs. 51% (P = 0047) with compara-
tor and an ORR of 436% vs. 128% with comparator
(P = 005), independently of whether or not they had pre-
viously received rituximab. The good response rate with
pixantrone was mainly due to CR (as opposed to CRu)
with 179% with pixantrone vs. 0% with comparator
(P = 0012). In those who had previously received ritux-
imab, the rate of ORR was 450% with pixantrone vs.
111% for comparator (P = 0033) and the rate of CR or
CRu was 300% vs. 56% with comparator (P = 0093).
The better PFS observed in patients with aggressive B-cell
NHL identified by central review compared with when dis-
ease was determined by site (HR, 052 vs. 083; data not
shown) suggests that the superior efficacy of pixantrone in
the patients with prior rituximab was not due to inclusion
of more patients with indolent disease based on site
pathology. The rate of CR or CRu in the pixantrone
group was almost double that of comparator in the
patients with prior rituximab treatment (200% vs. 115%
in patients receiving pixantrone at any line of treatment),
demonstrating the validity of pixantrone as a salvage treat-
ment. The observation of efficacy in patients previously
treated with rituximab is noteworthy, given that in many
other studies, receipt of prior rituximab therapy substan-
tially decreased the response rate to salvage therapies (Gis-
selbrecht et al, 2010). There was a non-statistically
significant trend towards improved OS in patients treated
with pixantrone that appeared to be influenced by the
number of prior regimens.
Pixantrone is conditionally approved by the European
Medicines Agency for the treatment of multiply relapsed or
refractory aggressive B-cell NHL. It was designed from the
structure of the anthracyclines with the intention of reducing
cardiotoxicity and maintaining antineoplastic efficacy. Pix-
antrone is an aza-anthracenedione (Volpetti et al, 2014) with
a different mode of action from that of the anthracyclines.
Thus, it forms stable DNA adducts thereby preventing DNA
replication, transcription and repair (Evison et al, 2007),
Table III. Outcomes in patients with aggressive B-cell non-Hodgkin lymphoma (determined by central review) and in patients receiving study
treatment as 3rd or 4th line.
Patients with aggressive B-cell non-Hodgkin lymphoma (N = 97)
With previous rituximab Without previous rituximab
Pixantrone Comparator P value* Pixantrone Comparator P value*
All patients (n = 97)
Number of patients 30 26 20 21
CR or CRu rate, n (%) 6 (200%) 3 (115%) 0481 3 (150%) 1 (48%) 0343
ORR, n (%) 9 (300%) 5 (192%) 0537 9 (450%) 3 (143%) 0043
Median PFS, months 35 23 63 35
HR (95% CI) 066 (038–114) 035 (017–070)
Median OS, months 60 46 161 78
HR (95% CI) 085 (048–150) 052 (024–111)
Patients receiving study treatment as 3rd or 4th line (n = 78)
Number of patients 20 18 19 21
CR or CRu rate, n (%) 6 (300%) 1 (56%) 0093 3 (158%) 1 (48%) 0331
ORR, n (%) 9 (450%) 2 (111%) 0033 8 (421%) 3 (143%) 0078
Median PFS, months 54 28 61 35
HR (95% CI) 052 (026–104) 036 (018–073)
Median OS, months 75 54 145 78
HR (95% CI) 076 (038–155) 056 (026–120)
CR, complete response; CRu, unconfirmed complete response; ORR, overall response rate; OS, overall survival; PFS, progression-free survival;
HR, hazard ratio; CI, confidence interval.
*P value versus comparator (Fisher exact test).
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potentially inhibiting cell division during mitosis (Beeharry
et al, 2013). Moreover, by contrast to anthracyclines, pix-
antrone is less likely to generate reactive oxygen species or
form long-lasting alcohol metabolites because of its inability
to bind iron and interact with topoisomerase II, both of
which have been linked to the generation of reactive oxygen
species and the induction of cardiotoxicity with the anthracy-
clines (Salvatorelli et al, 2013).
Retreatment of multiply relapsed or refractory patients
with aggressive NHL anthracyclines is problematic due to
long-term cardiotoxicity (Chatterjee et al, 2010). The use of
anthracycline-based regimens is associated with a 22%
A
B
Fig 2. Progression-free survival (PFS) in
patients with aggressive B-cell non-Hodgkin
lymphoma (determined by central review)
receiving study treatment as 3rd or 4th line
with (A) or without (B) previous rituximab
treatment.
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cumulative 10-year risk for cardiovascular disease, notably
with an excess of risk for cardiomyopathy leading to chronic
heart failure (incidence ratio 54) and stroke (incidence ratio
18) (Moser et al, 2006). There were no cumulative dose-
related declines in cardiac function with pixantrone, and the
adverse events reported were manageable and similar to the
results of the main trial (Pettengell et al, 2012).
The centralized histological review was a strength of the
main study (Pettengell et al, 2012) and enabled post hoc anal-
ysis of the efficacy of pixantrone in the exact population for
which it is intended in clinical practice. The concordance
between on-site histology and retrospective central review
(76%) was consistent with rates reported in the literature,
which range from 58% to 84% (Jones et al, 1977; Stel et al,
1989; Matasar et al, 2012), reinforcing both the results of the
main study and the post hoc analysis.
The small size of the population represents the main limi-
tation of our analysis. Stratified analyses were not conducted
for the analyses in this report due to the small strata sizes
and the resulting complications with the statistical analyses.
This unplanned post hoc analysis was not specifically designed
or powered to test the treatment effects in these subgroups.
The analysis was not adjusted for differences in baseline
characteristics and there was no correction for multiplicity.
Further studies are therefore important to confirm our
results.
In conclusion, pixantrone is more effective than compara-
tor in relapsed or refractory aggressive B-cell NHL in the 3rd
or 4th line setting, independently of previous rituximab ther-
apy. Pixantrone is an effective treatment that is conditionally
approved in the European Union for patients with multiply
relapsed and refractory aggressive B-cell NHL where there is
no standard therapy available. Thus, pixantrone offers an
efficient treatment alternative for these patients. The efficacy
of pixantrone versus gemcitabine both in combination with
rituximab is currently being studied in an international phase
3 trial (NCT01321541) in patients with relapsed or refractory
DLBCL or DLBCL transformed from follicular lymphoma,
who have all received previous therapy with R-CHOP (ritux-
imab, cyclophosphamide, doxorubicin, vincristine, pred-
nisolone) or equivalent. The clinical results of this trial are
expected in 2016.
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